FILED

FEB 06 2012

Carol E. Higbee, P.J.Cv.

DUANE MORRIS LLP
A Delaware Limited Liability Partnership
By: James J. Ferrelli, Esquire
By: Alan Klein, Esquire (*pro hac vice*)
1940 Route 70 East, Suite 200
Cherry Hill, NJ 08003-2171

IN RE ACCUTANE LITIGATION	**SUPERIOR COURT OF NEW JERSEY** **LAW DIVISION, ATLANTIC COUNTY** **CIVIL ACTION** **CASE CODE NO. 271**
IN RE ISOTRETINOIN LITIGATION **(APPLICABLE TO ALL CASES)**	**SUPERIOR COURT OF NEW JERSEY** **LAW DIVISION, ATLANTIC COUNTY** **DOCKET NO. ATL-L-1321-09** **CIVIL ACTION**

SUPPLEMENTAL ORDER ON STAY OF DISCOVERY
AND EXTENSION OF RESPONSIVE PLEADING DEADLINES
IN ALL CASES INVOLVING GENERIC ISOTRETINOIN DEFENDANTS

THIS MATTER having been brought before the Court at the case management conference on January 17, 2012.

WHEREAS, the parties having requested an extension of the stay imposed by the Orders dated July 19, 2011 and October 6, 2011 of all discovery in cases in which any entity that manufactures, markets, distributes, or sponsors an ANDA of a generic isotretinoin product is a party, and an extension of the deadline in any such cases to move, answer, or otherwise plead, to enable the plaintiffs to evaluate the impact on these cases of the decision by the Supreme Court

of the United States in the case of *Pliva, Inc., et al. v. Mensing*, and the Court having considered the request, and for good cause shown,

IT IS on this 6 day of Feb., 2012,

ORDERED as follows:

1. All discovery in any case in which an entity that manufactures, markets, distributes, or sponsors an ANDA of a generic isotretinoin product ("Generic Isotretinoin Defendant") is a party is hereby stayed *nunc pro tunc* from December 5, 2011 through the January 17, 2012 case management conference, and for an additional (60) days following the January 17, 2012 case management conference, through and including March 17, 2012. The stay of all discovery applies to all cases in which any Generic Isotretinoin Defendant is a party, including cases in which any Generic Isotretinoin Defendant is a co-defendant with any of the Roche Defendants ("Accutane co-ingestion cases"), and including the Accutane co-ingestion cases that currently are subject to the schedule for completion of core discovery; and

2. In any case in which a Generic Isotretinoin Defendant has been served but has not yet responded to the complaint, the deadlines for moving, answering, or otherwise pleading are hereby extended for an additional (90) days from the January 17, 2012 case management conference, through and including April 16, 2012.

AND IT IS FURTHER ORDERED that a copy of this Order shall be served by the Ranbaxy defendants' counsel upon all parties upon receipt.

Carol E. Higbee

Honorable Carol E. Higbee, P.J.Cv.